942
Participants
Start Date
May 15, 2020
Primary Completion Date
August 10, 2020
Study Completion Date
August 31, 2021
Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Placebo on a 0- and 28-day schedule
Two doses of placebo at the vaccination schedule of day 0,28
Placebo on a 0- and 14-day schedule
Two doses of placebo at the vaccination schedule of day 0,14
West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu
West China Second University Hospital
OTHER
Yunnan Center for Disease Control and Prevention
OTHER
Institute of Medical Biology, Chinese Academy of Medical Sciences
OTHER